JP2000014354A - Composition having anti-allergic or anti-inflammatory action - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain an anti-allergic or anti-inflammatory composition that can inhibit the histamine release and prostaglandin E2 production with side-effect reduced, can be taken by the patients for a long period of time, and is useful for atopic dermatitis by using plants, for example, Echinacea purpurea, sicklepod (Cassia torae) and the like. SOLUTION: This composition comprises (A) a plant, Echinacea purpourea, preferably in an amount of 40-60 pts.wt., and (B) one or more selected from the group consisting of Cassiae torae semen, rooibos (Aspalathus linearis), malt (Fructus hordei germinatus), safflower (Carthamus tinctorius), ginkgo leaves (Ginkgo biloba) and fruit of Monordicae fructus, preferably in an amount of 40-60 pts.wt. In as preferred embodiment, this composition is used to prepare food products having anti-inflammatory and anti-allergic actions or anti- inflammatory and anti-allergic pharmaceuticals.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to a composition having an anti-allergic or anti-inflammatory action.

[0002]

2. Description of the Related Art Echinacea has been found to have an immunostimulating action and an antiviral action when used alone.

[0003]

DISCLOSURE OF THE INVENTION The present invention relates to a composition having anti-inflammatory or anti-allergic activity, having few side effects and capable of being taken for a long period of time, a food containing the composition, an anti-inflammatory agent and The purpose is to provide an antiallergic agent.

[0004]

Means for Solving the Problems As a result of diligent studies, the present inventor has found that echinacea is combined with at least one selected from the group consisting of ebisugusa, rooibos, malt, safflower, ginkgo leaf and arhat fruit to obtain echinacea. It has been found that an antiallergic action or an antiinflammatory action that is even higher than that of a single agent is exhibited. That is, an object of the present invention is to provide the following composition and a food, an anti-inflammatory agent and an anti-allergic agent containing any of the compositions.

[0005] 1. A composition comprising (1) Echinacea and (2) at least one selected from the group consisting of Ebisugusa, Rooibos, malt, safflower, ginkgo biloba, and Arhat fruit.

[0006] 2. (1) A composition comprising 40 to 60 parts by weight of echinacea, and (2) 40 to 60 parts by weight of at least one selected from the group consisting of ibis grass, rooibos, malt, safflower, ginkgo biloba, and arhat.

[0007] 3. Echinacea, Ebisugusa, Rooibos,
2. A composition comprising malt, safflower, ginkgo biloba and arhat fruit.
Or the composition according to 2. 4. A food having an anti-inflammatory action, comprising the composition according to any one of the above 1 to 3.

[0008] 5. A food having an antiallergic effect, comprising the composition according to any one of the above 1 to 3.

6. An anti-inflammatory agent comprising the composition according to any one of the above 1 to 3.

[0010] 7. An antiallergic agent comprising the composition according to any one of the above 1 to 3.

[0011]

BEST MODE FOR CARRYING OUT THE INVENTION Echinacea (scientific name: Echinacea purpurea), Ebisugusa (scientific name: Cassia) used in the present invention
e torae semen), Rooibos (scientific name: Aspalathus linear)
is), malt (scientific name: Fructus hordei germinatus), safflower (scientific name: Carthamus tinctorius), ginkgo biloba (scientific name: Ginkgo biloba) and arhat fruit (scientific name: Momordica)
e fructus) can be used commercially regardless of its shape and place of origin. For example, echinacea uses leaves and stems, Ebisugusa leaves, rooibos leaves and stems, malt is germinated and dried, safflower is flowers, ginkgo leaves are leaves, and arhat fruit is fruit. Can be mentioned. Echinacea is from Germany, Ebisugusa is from India, Rooibos is from South Africa, malt is from Japan, safflower is from China, ginkgo biloba is from Japan, and Rakanka is from China. Can be

The composition of the present invention includes (1) Echinacea and (2) Ebisugusa, Rooibos, malt, safflower,
Examples include those obtained by appropriately blending at least one selected from the group consisting of ginkgo biloba and Arkanka, an extract thereof, a decoction, and an extract. The composition ratio is not limited, but preferably (1) 40 to 60 parts by weight of echinacea, (2) ebisugusa, rooibos, malt, safflower,
40 to 60 parts by weight of at least one selected from the group consisting of ginkgo biloba and Arkanka fruit, more preferably (1) 45 to 55 parts by weight of echinacea, (2) Ebisugusa, rooibos, malt, safflower, Ginkgo biloba and Arkanka At least one selected from the group consisting of 45 to 55 parts by weight. This is because at this composition ratio, a higher antiallergic action or antiinflammatory action was exhibited.

The shape of the composition of the present invention is not particularly limited, and may be appropriately determined according to each use. For example, when used as a tea bag, the blended product may be appropriately pulverized. When the extract or decoction is used as a beverage, it may be extracted or decocted with water or alcohol. The form of the extract or concentrate obtained by concentrating or drying the decoction is not particularly limited, and examples thereof include liquid, solid, and powder forms.

[0014] Foods containing the composition of the present invention include:
Although not particularly limited, tea leaves for beverages, beverages in which the composition has been extracted or brewed in water or alcohol, such as herbal teas and liqueurs, and crushed, extracted, brewed or extracted blends of each component Foods containing the extract, for example, beverages, candies, gums, jellies, tablets and the like are exemplified. It can also be used as a health food, functional food, or food for specified health use.

For example, when ingesting as a herbal tea, a tea bag filled with about 3 g of the composition of the present invention is placed in 500 to 1000 ml of hot water and boiled for about 3 minutes. The anti-allergic or anti-inflammatory agent of the present invention, using the composition of the present invention and a pharmaceutically acceptable carrier,
It is prepared as a pharmaceutical composition according to the usual method.
Examples of the carrier used here include various types commonly used for ordinary drugs, for example, excipients, binders, disintegrants, lubricants, coloring agents, surfactants and the like.

The pharmaceutical dosage form when using the anti-allergic or anti-inflammatory agent of the present invention is not particularly limited, and can be appropriately selected depending on the purpose of treatment and prevention.
Examples include oral preparations such as pills, granules, capsules, solutions, suspensions, and emulsions, and parenteral preparations such as lotions, ointments, and patches. These formulations are formulated by conventional manufacturing methods commonly known in the art.

For example, when preparing a lotion,
The anti-allergic agent or anti-inflammatory agent of the present invention, a base, a stabilizer, a wetting agent, a preservative, a surfactant, a suspending agent, an emulsifier, a fragrance, etc., which are commonly used, are blended as necessary. It is mixed with an aqueous liquid and formulated. As the base, beeswax, hydrophilic ointment, benzyl benzoate and the like can be mentioned, and as the aqueous liquid, ordinary water or purified water may be used, and non-aqueous solvents such as ethanol, glycerin and glycols may be used. Can be used. Examples of the preservative include methyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, and the like.

[0018]

Industrial Applicability The composition of the present invention has an effect of suppressing histamine release and an effect of suppressing the production of prostaglandin E ₂ (PGE ₂ ). In the case of suppressing histamine release, it has an effect of preventing or treating a disease in which histamine is deeply involved in the diseased body, for example, allergic diseases such as atopic dermatitis, allergic rhinitis, hay fever and urticaria. In addition, when the production of PGE ₂ is suppressed, the progress of inflammation can be prevented, treated or suppressed.

The composition of the present invention, a food containing the composition and an antiallergic agent are effective for the prevention or treatment of allergic diseases such as atopic dermatitis, allergic rhinitis, hay fever and urticaria. Sneezing,
Prevention, elimination or alleviation of symptoms such as runny nose, itchy skin, eyes and nose, nasal congestion, lacrimation and rash.

The composition of the present invention, a food containing the composition, and an anti-inflammatory agent have an action of preventing inflammation or repairing inflamed tissues, and include asthma, allergic inflammation and the like. Airway, conjunctiva, nose, inflammation of the pharyngeal mucosa, or various acute inflammation including inflammation due to sunburn or burns or chronic inflammation such as rheumatism,
Prevent, eliminate or alleviate the symptoms.

Further, when an effective amount of each component is contained, the composition of the present invention, the food containing the composition, and the anti-inflammatory agent exhibit the effects observed when each component is used alone. Also have. For example, Echinacea
It has immunostimulatory and antiviral effects. Ebisugusa has antihypertensive and laxative effects, rooibos has SOD (superoxide dismutase) -like effect, malt has stomach and digestive effect, safflower has cholesterol deposition prevention, and ginkgo biloba has blood flow improvement and It is known that circulatory disorder improving effect and Arkanka have antitussive and antipyretic effects.

The ingredients of the food composition of the present invention, such as echinacea, are known as herbs and herbal medicines, respectively, and can be taken for a long time without worrying about toxicity. Conventional drugs with anti-inflammatory or anti-allergic effects (for example, steroid drugs) cause various side effects,
Although careful attention must be paid to the dose and the number of times of administration, the composition of the present invention has no side effects and can be easily taken as food.

[0023]

EXAMPLES In the following, various experiments were conducted to explain the present invention in more detail. The present invention is not limited to these examples.

<Method for Preparing Extract of Echinacea Composition> 50 parts by weight of crushed echinacea leaves and stem, Ebisugusa 1
Take 200 g of a food composition containing 6.5 parts by weight, 15 parts by weight of rooibos, 10.0 parts by weight of malt, 5.0 parts by weight of safflower, 2.5 parts by weight of ginkgo biloba, and 1.0 part by weight of Arhat fruit, and boil water The mixture was added to 6000 ml, gently boiled for 10 minutes while stirring, cooled, and filtered. The filtrate was concentrated using a rotary evaporator at a temperature of 40 ° C. or lower until the volume became about 1/10. The obtained concentrate was freeze-dried (yield 53.7 g).

<Method for Preparing Extract of Echinacea Alone> An extract was prepared in the same manner as for the echinacea composition using 200 g of crushed echinacea leaves and stems.

Example 1 Effect of RBL-2H3 cells on histamine release The inhibitory effect of RBL-2H3 cells, a rat basophil leukemia cell line, on histamine release was examined.

RBL-2H3 cells sensitized with monoclonal mouse IgE anti-dinitolphenol (DNP) antibody (0.32 μg / ml) for 1 hour, washed, added with various concentrations of echinacea extract, and added for 30 minutes Cultured. Further, in the presence of an extract having the same concentration, DNP-modified bovine serum albumin (0.1 μg / ml) as an antigen was added, and the cells were cultured for 40 minutes. After completion of the culture, the amount of histamine in the culture supernatant and in the cell lysate was measured and expressed as a release rate.

Comparative Example 1 With respect to the extract of echinacea alone, the effect on histamine release was examined in the same manner.

FIG. 1 shows the results of Example 1 and Comparative Example 1. At the same time, the results of the case without sensitization (indicated as “unsensitized” in the figure) and the control (the case with antigen stimulation without any addition after sensitization, indicated as “sensitized” in the figure) are shown. The extract of the echinacea composition exhibited a higher histamine release inhibitory action than the control and echinacea alone. The same effect can be obtained with the composition having the composition ratio shown in the present invention. In Comparative Example 1, an extract of echinacea alone was used, however, ebisugusa, rooibos, malt,
When the safflower, ginkgo biloba and Arkanka were used alone, the histamine release inhibitory effect was much weaker than that of the extract of Example 1.

It was confirmed by WST-1 assay that these histamine release inhibitory effects were not due to cytotoxicity. That is, RBL-2H3 cells were cultured for 70 minutes in the presence of the extract at the concentration used in the test, washed, and
-1 (2- (4-Iodophenyl) -3- (4-nitrophenyl) -5- (2,4-disulfophenyl) -2H-tetrazolium) solution (Premix WST-1 assay reagent, Takara Shuzo) Was added. This was reacted for 30 minutes, and the formazan produced was measured at an absorbance of 450-650 nm,
It was compared with the case without the extract. As a result, the amount of formazan generated by the action of living cells did not change even when the extract was added.

Examples 2 and 3 Effect of human skin fibroblasts on cyclooxygenase-2 (COX-2) expression The inhibitory effect of human skin fibroblasts on COX-2 expression induced by IL-1β or TNFα was determined by prostaglandin. It was examined as an inhibitory effect on E ₂ (PGE ₂ ) production.

Extracts of the echinacea composition at various concentrations were added to human skin fibroblasts and cultured for 30 minutes. Then, IL-1β (50 U / ml, Example 2) or TNFα was co-existed with the extract at the same concentration. (50 U / ml, Example 3) was added, and the cells were cultured for 2 hours or 1 hour, respectively. After culturing, the cells were washed, and only the culture solution was added to the cells. The cells were cultured for 4 hours in the case of IL-1β stimulation and 5 hours in the case of TNFα stimulation. The amount of PGE _{2 in} the supernatant after the culture was measured using an ELISA kit (manufactured by Amersham).

Comparative Examples 2 and 3 In the same manner, the extract of the echinacea-only product also exhibited a suppressive effect on the transcriptional activity in COX-2 expression stimulated by IL-1β (Comparative Example 2) or TNFα (Comparative Example 3). It was examined as an inhibitory effect on PGE ₂ production.

FIG. 2 shows the results of Example 2 and Comparative Example 2, and FIG. 3 shows the results of Example 3 and Comparative Example 3. In each of the figures, the results for the case of no stimulation and for the control (cultured without adding an extract at the time of stimulation, indicated as stimulation in the figures) are also shown. In the production of PGE ₂ stimulated by IL-1β or TNFα, the extract of the echinacea composition was higher than that of the control and echinacea alone.
It showed a high inhibitory effect. The same effect can be obtained with the composition having the composition ratio shown in the present invention. In Comparative Examples 2 and 3, the extract of echinacea alone was used. However, when using only the products of Ebisugusa, Rooibos, malt, safflower, ginkgo biloba and Arhat, the inhibitory effect on PGE ₂ production was found in Example 2. Or it was much weaker than the extract of 3.

[0035] It was confirmed by WST-1 assay and the lactate dehydrogenase (LDH) release from cells that these COX-2 expression suppressing effects were not caused by cell damage. That is, fibroblasts were cultured for 6 hours and 30 minutes in the presence of the extract at the concentration used in the test, and the culture solution was collected. The cells are washed and the WST-1 solution (Premix WS
T-1 assay reagent (Takara Shuzo) was added. This one
After reacting for hours, the generated formazan is 450-650 nm
Was measured, and compared with the case where no extract was added. As a result, the amount of formazan produced by the action of living cells did not change even when the extract was added.

On the other hand, the LDH activity in the culture was determined to be LDH-
Using a cytotoxicity test kit (manufactured by Wako Pure Chemical Industries), the amount of LDH in the culture solution leaked from the cells was calculated by measuring the absorbance at 560 nm. At this time, as a positive control for cytotoxicity, 0.1% Tween 20 was added to the cells, and the LDH release rate in this case was 100%.
%. As a result, even when the extract having the concentration used in the test was added, there was no change in the LDH release rate as compared with the control.

[Brief description of the drawings]

FIG. 1 is a graph showing the effect of various concentrations of extracts on histamine release of sensitized RBL-2H3 cells upon antigen stimulation. The results were average ± standard deviation (n = 3)
Indicated by

FIG. 2 is a graph showing the effect of various concentrations of extracts on IL-1β stimulation-induced PGE ₂ production. The results were shown as the average value ± standard deviation (n = 3).

FIG. 3 is a graph showing the effect of the extract on the production of PGE ₂ by TNFα stimulation. The results were shown as the average value ± standard deviation (n = 3).

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification code FI Theme coat ゛ (Reference) A61K 35/78 ABF A23L 2/00 FF Term (Reference) 4B017 LC03 LE01 LE09 LG13 LG15 LP01 LP02 LP03 LP14 4B018 LB01 LB08 LB10 LE01 LE03 LE05 MS11 MS16 4C088 AB02 AB19 AB26 AB59 AB73 AC03 AC04 AC05 BA06 BA08 BA09 BA10 MA07 MA52 NA14 ZB11 ZB13

Claims (7)

[Claims] (1) Echinacea and (2) Ebisugusa,
A composition comprising at least one member selected from the group consisting of rooibos, malt, safflower, ginkgo biloba, and arhat. (1) 40 to 60 parts by weight of echinacea,
(2) A composition comprising 40 to 60 parts by weight of at least one selected from the group consisting of lobster, rooibos, malt, safflower, ginkgo biloba, and arhat fruit. 3. The composition according to claim 1, comprising echinacea, ibis grass, rooibos, malt, safflower, ginkgo biloba and arhat. 4. A food having an anti-inflammatory effect comprising the composition according to claim 1. 5. A food having an antiallergic effect comprising the composition according to claim 1. 6. An anti-inflammatory agent comprising the composition according to claim 1. 7. An antiallergic agent comprising the composition according to claim 1.